GP
AZN icon

GLG Partners’s AstraZeneca AZN Stock Holding History

GLG Partners’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-6,124
Closed -$390K – 459
2015
Q3 		$390K Buy
+6,124
New +$403K 0.01% 412
2014
Q3 		– Sell
-51,466
Closed -$3.82M – 422
2014
Q2 		$3.82M Buy
+51,466
New +$3.72M 0.09% 208

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return
CI
Cambiar Investors Denver, Colorado $2.3B AUM 24.77% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
SCCM
Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

GLG Partners's AZN Position: Q4 2015 in Review

GLG Partners sold out of AstraZeneca (AZN) in Q4 2015, closing a stake of 6,124 shares — an estimated $390K sold.

GLG Partners first reported a position in AZN in Q2 2014 and held it in 2 quarters. The position peaked at $3.82M in Q2 2014. 390 funds tracked by Wall St. Rank hold AZN as of Q4 2015.

  • GLG Partners reported no remaining AstraZeneca position as of Q4 2015 after selling out during the quarter.
  • GLG Partners sold 6,124 AstraZeneca shares in Q4 2015, an estimated $390K.
  • GLG Partners first reported a position in AstraZeneca in Q2 2014 and held it in 2 quarters.
  • GLG Partners's AstraZeneca position peaked at $3.82M in Q2 2014.
  • 390 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2015.

Based on GLG Partners's 13F filing for Q4 2015, filed 16 Feb 2016.